Literature DB >> 11423984

Distinct pattern of p53 phosphorylation in human tumors.

T Minamoto1, T Buschmann, H Habelhah, E Matusevich, H Tahara, A L Boerresen-Dale, C Harris, D Sidransky, Z Ronai.   

Abstract

The protein product of the tumor suppressor gene p53 is phosphorylated on multiple residues by several protein kinases. Using a battery of 10 antibodies developed against different phosphorylated and acetylated residues of p53, we compared the pattern of p53 phosphorylation and acetylation in tumor-derived cell lines, tumor samples, and non-neoplastic cells. Irrespective of tumor types or the presence of p53 mutation, phosphorylation and acetylation of p53 was substantially higher in samples obtained from tumor tissues than those found in non-transformed samples. Among the 10 sites analysed, phosphorylation of residues 15, 81, 392, and acetylation were among the more frequent modifications. Analysis of two of the more abundant phosphorylation or acetylation sites on p53 is sufficient to detect 72% of tumor-derived p53 proteins. The distinct pattern of p53 phosphorylation and acetylation in human tumors may offer a new means to monitor the status and activity of p53 in the course of tumor development and progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423984     DOI: 10.1038/sj.onc.1204458

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.

Authors:  Kenzo Ohara; Takayuki Ohkuri; Takumi Kumai; Toshihiro Nagato; Yui Nozaki; Kei Ishibashi; Akemi Kosaka; Marino Nagata; Shohei Harabuchi; Mizuho Ohara; Kensuke Oikawa; Naoko Aoki; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Mechanisms of p53 activation and physiological relevance in the developing kidney.

Authors:  Karam Aboudehen; Sylvia Hilliard; Zubaida Saifudeen; Samir S El-Dahr
Journal:  Am J Physiol Renal Physiol       Date:  2012-01-11

3.  Baking a mass-spectrometry data PIE with McMC and simulated annealing: predicting protein post-translational modifications from integrated top-down and bottom-up data.

Authors:  Stuart R Jefferys; Morgan C Giddings
Journal:  Bioinformatics       Date:  2011-03-15       Impact factor: 6.937

4.  Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.

Authors:  Jeffrey S Buzby; Shirley A Williams; Lana Schaffer; Steven R Head; Diane J Nugent
Journal:  Cancer Genet       Date:  2017-01-09

5.  Simultaneous determination of two phosphorylated p53 proteins in SCC-7 cells by an ICP-MS immunoassay using apoferritin-templated europium(III) and lutetium(III) phosphate nanoparticles as labels.

Authors:  Xiao Yin; Beibei Chen; Man He; Bin Hu
Journal:  Mikrochim Acta       Date:  2019-06-11       Impact factor: 5.833

Review 6.  Posttranslational phosphorylation of mutant p53 protein in tumor development.

Authors:  Manabu Matsumoto; Mutsuo Furihata; Yuji Ohtsuki
Journal:  Med Mol Morphol       Date:  2006-06       Impact factor: 2.309

7.  Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.

Authors:  Hongsai Chen; He Huang; Jingjing Zhao; Zhigang Wang; Mengling Chang; Lu Xue; Weidong Zhu; Yongchuan Chai; Gen Li; Zhaoyan Wang; Hao Wu
Journal:  J Neurooncol       Date:  2019-05-02       Impact factor: 4.130

Review 8.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

9.  p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.

Authors:  Sally Hopkins-Donaldson; Larisa L Belyanskaya; Ana Paula Simões-Wüst; Brigitte Sigrist; Stefanie Kurtz; Uwe Zangemeister-Wittke; Rolf Stahel
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

10.  Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.

Authors:  Sárka Pospísilová; Václav Brázda; Katerina Kucharíková; M Gloria Luciani; Ted R Hupp; Petr Skládal; Emil Palecek; Borivoj Vojtesek
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.